Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Argus Health
Johnson and Johnson
Medtronic
US Department of Justice
Queensland Health

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,642,210

« Back to Dashboard

Which drugs does patent 6,642,210 protect, and when does it expire?

Patent 6,642,210 protects LEXISCAN and is included in one NDA.

This patent has twenty-nine patent family members in twenty-three countries.

Summary for Patent: 6,642,210
Title: 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
Abstract:N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as A.sub.2 A-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.
Inventor(s): Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Freemont, CA), Palle; Venkata P. (Sunnyvale, CA)
Assignee: CV Therapeutics, Inc. (Palo Alto, CA)
Application Number:10/018,446
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,642,210
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Formulation;

Drugs Protected by US Patent 6,642,210

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,642,210

PCT Information
PCT FiledJune 21, 2000PCT Application Number:PCT/US00/40281
PCT Publication Date:December 28, 2000PCT Publication Number: WO00/78779

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Harvard Business School
Boehringer Ingelheim
US Army
Deloitte
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.